Konstantinos Tryfonidis
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Immunotherapy and Biomarkers, BRCA gene mutations in cancer
Most-Cited Works
- → 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer(2016)2,013 cited
- → Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study(2020)426 cited
- → Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program(2017)389 cited
- → Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study(2015)375 cited
- → 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age(2021)342 cited
- → Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer(2024)335 cited
- → Management of locally advanced breast cancer—perspectives and future directions(2015)186 cited
- → Endocrine treatment in breast cancer: Cure, resistance and beyond(2016)136 cited
- → VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC(2021)131 cited
- → LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer(2023)130 cited